Physician profile
David Dheurle
NPI 1912098435
$283.26
in general payments reported to CMS, 2019-2025
11 companies · $47.07 in 2025
The $47.07 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.44 · 2020: $36.99 · 2021: $37.10 · 2023: $49.98 · 2024: $79.68 · 2025: $47.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $61.53 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $40.40 | 2020-2021 | |
| Harrow Eye, LLC | $28.39 | 2025 | Vevye |
| Alcon Vision LLC | $24.79 | 2023 | Simbrinza |
| Genentech USA, INC. | $23.13 | 2024 | Vabysmo |
| Oyster Point Pharma, INC. | $20.21 | 2024 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $18.68 | 2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $18.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.29 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dheurle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.